AZD8055 CAS:1009298-09-2

CAS NO: 1009298-09-2
AZD8055 CAS:1009298-09-2
Description Review
Description

AZD8055 is a small molecule inhibitor of the mammalian target of rapamycin (mTOR) kinase, which plays a key role in regulating cell growth and proliferation. It is currently being investigated for its potential therapeutic use in various types of cancer.

Chemical name: 2-(2-chloro-4-methylphenyl)-N-(1H-pyrazol-3-yl)-5-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]pyrimidine-4-carboxamide Molecular formula: C22H30ClN7O Formula weight: 441.98 g/mol CAS No: 1009298-09-2

Top ten keywords from Google and Synonyms:

  1. mTOR inhibitor
  2. Cancer treatment
  3. AZD8055 mechanism
  4. Renal cell carcinoma
  5. Breast cancer
  6. Glioblastoma
  7. Tyrosine kinase inhibitors
  8. Signal transduction
  9. Cell proliferation
  10. PI3K/AKT/mTOR pathway

Health benefits of this product: AZD8055 has shown promising results in preclinical studies for its potential use in treating various types of cancers, such as renal cell carcinoma, breast cancer, and glioblastoma. Its ability to inhibit mTOR, a key regulator of cell growth and proliferation, may lead to the suppression of tumor growth and the induction of apoptosis, or programmed cell death.

Potential effects: Studies have demonstrated that AZD8055 has potential therapeutic effects in various types of cancer. It has also been shown to have potential in treating other diseases, such as diabetes and neurodegenerative disorders.

Product mechanism: AZD8055 works by inhibiting the activity of mTOR, a key enzyme in the PI3K/AKT/mTOR signaling pathway. This pathway is critical for regulating cell growth and proliferation, and its dysregulation can lead to uncontrolled cell growth and tumor formation. By inhibiting mTOR, AZD8055 can block the downstream activation of key signaling molecules such as AKT and S6 kinase, which are essential for cell survival and growth. This leads to apoptosis, or programmed cell death, and the suppression of cancer cell growth.

Safety: As with any medication, safety is a concern when using AZD8055. Studies have shown that it is generally well-tolerated and has a good safety profile. However, like other mTOR inhibitors, it can cause side effects such as diarrhea, nausea, vomiting, and fatigue. It is important to consult with a healthcare provider before using AZD8055 and to closely monitor any potential side effects.

Side effects: Some of the common side effects of AZD8055 include gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain. Other potential side effects include fatigue, headache, and rash. In rare cases, AZD8055 can cause serious side effects such as liver toxicity and lung inflammation, so close monitoring is recommended.

Dosing information: AZD8055 is typically administered orally as a tablet. The optimal dose and duration of treatment will vary depending on the individual patient and the type of disease being treated. It is important to follow dosing instructions carefully and to consult with a healthcare provider before beginning treatment with AZD8055.

Conclusion: AZD8055 is a promising small molecule inhibitor that has demonstrated potential in treating various types of cancer by inhibiting the activity of mTOR, a key regulator of cell growth and proliferation. Although it has a good safety profile, potential side effects must be closely monitored. Further research is needed to fully explore the therapeutic potential of AZD8055 and its applications in treating various diseases.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code